Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in small bowel Crohn's disease
NCT03142321Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2018
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by Washington University School of Medicine. Primary endpoint: Radiological Response at 52 weeks. Started Jun 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03142321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142321.